This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of cookies and the other terms of our Privacy Policy. For more information, please visit our Privacy Policy

The psychosocial burden of Fabry

People with Fabry can experience anxiety, depression, and other psychological symptoms1

UNCOVER HOW FABRY CAN IMPACT YOUR PATIENTS’ MENTAL HEALTH

Fabry from a female perspective

Women with Fabry may experience the disease differently than men2

EXAMINE DISTINCT AREAS OF FOCUS FOR WOMEN WITH FABRY

The physical burden of Fabry

Fabry impacts a variety of organ systems in distinct ways, including the cardiovascular, renal, and neurological systems3

The psychosocial burden of Fabry

People with Fabry can experience anxiety, depression, and other psychological symptoms1

UNCOVER HOW FABRY CAN IMPACT YOUR PATIENTS’ MENTAL HEALTH

Fabry from a female perspective

Women with Fabry may experience the disease differently than men2

EXAMINE DISTINCT AREAS OF FOCUS FOR WOMEN WITH FABRY

Let’s rethink Fabry together

We’ve come a long way—and together, we can go even further

SEE HOW TO TAKE ACTION IN FABRY

Educational resources

We’ve compiled educational resources for you and your patients

DOWNLOAD RESOURCES

Stay updated on the latest news

We’re on the forefront of Fabry together

SIGN UP FOR OUR EMAIL PROGRAM

Chiesi Global Rare Diseases building Chiesi Global Rare Diseases building Chiesi Global Rare Diseases building

Chiesi Global Rare Diseases: your partner in rethinking Fabry

Chiesi is the largest global pharmaceutical company to be awarded B Corporation Certification, a recognition of high social and environmental standards. Putting patients first is the heart of everything we do—we’re dedicated to building a brighter future for the ~350,000,000 patients with rare diseases worldwide.4

We’re fully invested in Fabry and the Fabry community.

WATCH GIACOMO CHIESI, HEAD OF GLOBAL RARE DISEASES, DISCUSS THE CHIESI COMMITMENT TO FABRY

References: 1. Laney DA, Bennett RL, Clarke V, et al. Fabry disease practice guidelines: recommendations from the National Society of Genetic Counselors. J Genet Counsel. 2013;22(5):555-564. doi:10.1007/s10897-013-9613-3. 2. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. doi:10.1186/1750-1172-5-30. 3. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138(4):338-346. doi:10.7326/0003-4819-138-4-200302180-00014. 4. Boycott KM, Lau LPL, Cutillo CM, Austin CP. International collaborative actions and transparency to understand, diagnose, and develop therapies for rare diseases. EMBO Mol Med. 2019;11(5):1-7. doi:10.15252/emmm.201910486.